Benzinga | Jun 30, 2021 06:25AM EDT

HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $25

HC Wainwright & Co. analyst Patrick Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $35 to $25.